연구용
제품 번호: S7995
| 분자량 | 395.88 | 화학식 | C15H18FN3O2S.Cl H.2 H2 O |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 887375-67-9 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | K-115 hydrochloride dihydrate | Smiles | CC1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)F.O.O.Cl | ||
|
In vitro |
Water : 79 mg/mL
DMSO
: 26 mg/mL
(65.67 mM)
Ethanol : 5 mg/mL |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
ROCK2
(Cell-free assay) 19 nM
ROCK1
(Cell-free assay) 51 nM
|
|---|---|
| 시험관 내(In vitro) |
In monkey trabecular meshwork (TM) cells, Ripasudil induces retraction and rounding of cell bodies as well as disruption of actin bundles. In Schlemm's canal endothelial (SCE) cells, Ripasudil significantly decreases transendothelial electrical resistance (TEER), increases the transendothelial flux of FITC-dextran, and disrupts cellular localization of ZO-1 expression. |
| 키나아제 분석 |
Kinase Inhibition Assay
|
|
ROCK 1 (0.75 ng/μL) and ROCK 2 (0.5 ng/μL) are incubated with various concentrations of K-115, Y-27632, or HA-1077 at 25 °C for 90 min in 50 mmol/L Tris-HCl buffer (pH 7.5) containing 100 mmol/L KCl, 10 mmol/L MgCl2, 0.1 mmol/L EGTA, 30 μmol/L Long S6 Kinase Substrate peptide, and 1 μmol/L ATP in a total volume of 40 μL. PKACα, PKC, and CaMKIIα are also incubated with various concentrations of K-115, Y-27632, or HA-1077. PKACα (0.0625 ng/μL) is incubated at 25 °C for 30 min in 40 mmol/L Tris-HCl buffer (pH 7.5) containing 20 mmol/L MgCl2, 1 mg/mL BSA, 5 μmol/L Kemptide peptide substrate, and 1 μmol/L ATP in a total volume of 40 μL. PKC (0.025 ng/μL) is incubated at 25 °C for 80 min in 20 mmol/L Tris-HCl buffer (pH 7.5) containing 20 mmol/L MgCl2, 0.4 mmol/L CaCl2, 0.1 mg/mL BSA, 0.25 mmol/L EGTA, 25 ng/mL phosphatidylserine, 2.5 ng/mL diacylglycerol, 0.0075% Triton-X-100, 25 μmol/L DTT, 10 μmol/L Neurogranin (28–43) peptide substrate, and 1 μmol/L ATP in a total volume of 40 μL. CaMKIIα (0.025 ng/μL) is incubated at 25 °C for 90 min in 50 mmol/L Tris-HCl buffer (pH 7.5) containing 10 mmol/L MgCl2, 2 mmol/L CaCl2, 0.04 mg/mL BSA, 16 μg/mL purified calmodulin from bovine testis, 500 μmol/L DTT, 50 μmol/L Autocamitide 2, and 1 μmol/L ATP in a total volume of 40 μL. After incubation, 40 μL of Kinase-Glo Luminescent Kinase Assay solution is added, and allowed to remain at 25 °C for 10 min, and Relative Light Units (RLU) are measured using a luminometer. The RLU without test compound is set as 100% (Control value), and that without enzyme and compound is set as 0% (Normal value). The reaction rate (% of control) is then calculated from the RLU with addition of each concentration of test compounds, and the 50% inhibitory concentrations (IC50) are determined by logistic regression analysis using SAS.
|
|
| 생체 내(In vivo) |
In albino rabbits and monkeys, topical instillation of Ripasudil significantly reduces intraocular pressure (IOP) with maximum IOP reduction of 8.55 mmHg and 4.36 mmHg at 0.5 % and 0.4%, respectively. Ripasudil (1 mg/kg daily, p.o.) exerts a neuroprotective effect on retinal ganglion cell (RGC) after optic nerve crush (NC) by suppressing oxidative stress through pathways involving the Nox family in a mouse model. |
참조 |
|
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT04621136 | Completed | Retinopathy of Prematurity |
Kyushu University |
November 1 2020 | Phase 1|Phase 2 |